NCT03093116 2025-07-10TRIDENT-1Turning Point Therapeutics, Inc.Phase 1/2 Recruiting500 enrolled 2 FDA
NCT04774952 2025-04-15Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid TumorsRevolution Medicines, Inc.Phase 1 Completed58 enrolled